Familial hypertrophic cardiomyopathy: basic concepts and future molecular diagnostics

Area of Science:

• Cardiology
• Genetics
• Molecular Biology

Background:

• Familial hypertrophic cardiomyopathies (FHC) are the most prevalent genetic heart diseases in the U.S., affecting approximately 1 in 500 individuals.
• Characterized by increased cardiac wall thickness, FHC is an autosomal dominant condition often presenting asymptomatically, masking its potentially fatal consequences, including sudden cardiac death in young individuals and adults.
• The genetic heterogeneity of FHC, primarily involving sarcomere proteins, presents significant challenges for accurate and timely diagnosis using current methods.

Purpose of the Study:

• To review the pathophysiology of familial hypertrophic cardiomyopathies.
• To discuss the rationale and importance of genetic testing for FHC.
• To evaluate the limitations and advantages of current and emerging diagnostic technologies for FHC.

Main Methods:

• Review of current literature on FHC genetics, pathophysiology, and diagnostics.
• Discussion of array-based resequencing using high-throughput microarray technology for mutation identification.
• Exploration of next-generation sequencing methodologies for enhanced FHC diagnosis.

Main Results:

• FHC diagnosis is complicated by genetic heterogeneity, impacting the effectiveness of current diagnostic tools.
• Array-based resequencing represents a novel high-throughput approach for identifying FHC-associated mutations.
• Next-generation sequencing holds promise for improving the accuracy and efficiency of FHC diagnosis.

Conclusions:

• Accurate and rapid diagnosis of FHC is crucial for early intervention and reducing mortality rates.
• Advanced molecular technologies, including array-based resequencing and next-generation sequencing, are poised to revolutionize FHC diagnostics.
• Further research and clinical implementation of these advanced methods are essential for better management of FHC patients.